clinical trial · NCT06059547
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Bladder CancerAdult Solid TumorNivolumabVisugromab (CTL-002)Placebo
brief summary
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical Cystectomy (RC)/Re-TURBT who cannot receive or refuse to receive cisplatin-based chemotherapy.
started
Sep 6, 2023
primary completion
Oct 16, 2025
completion
Oct 16, 2026
last updated
Dec 11, 2025
official title
A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol